Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Contrast Clear all
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer

NCT01821105
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer, Stage IV B Colon Cancer, Stage IV B Rectal Cancer
Interventions
PET Scan, CT Scan, fludeoxyglucose F 18, computer-aided detection/diagnosis
Procedure · Radiation
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Sep 2, 2026, 9:18 PM EDT
Recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
2,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
478
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 354 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1 Interventional

Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary

NCT00626873
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Definity, medical chart review
Drug · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated No phase listed Observational

Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

NCT01064895
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
Interventions
Benephit catheter for Targeted Renal Therapy
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Miami, Florida • Miramar, Florida • Blackfoot, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated Early Phase 1 Interventional

Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer

NCT03280277
View directory record Official record
Conditions
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Sep 2, 2026, 9:18 PM EDT
Completed No phase listed Observational

Measuring Non-Enhancing Glioblastoma Progression

NCT00777686
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
MRI/MRS Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

NCT05061979
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
BAY1747846
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 2, 2026, 9:18 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT05969496
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Blood Transfusion Reduction - QI Project

NCT04823273
View directory record Official record
Conditions
Blood Transfusion
Interventions
General improvement, In-line help text, Interruptive alert
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Not listed
Enrollment
1,640 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility

NCT01379183
View directory record Official record
Conditions
Healthy
Interventions
Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Not applicable Interventional

Intraoperative Radiotherapy for Early Stage Breast Cancer

NCT01189851
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraoperative Radiotherapy
Device
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
48 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated Phase 2 Interventional

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

NCT03942601
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Temsirolimus, Temsirolimus and dexamethasone sodium phosphate
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen

NCT01710449
View directory record Official record
Conditions
COPD, Asthma, Cystic Fibrosis, Emphysema, Small Airways Diseases
Interventions
perfluorinated gas/oxygen mixture
Drug
Lead sponsor
Hal C Charles
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2013 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated No phase listed Observational

Ultrasound and Other Images of Artery Blockages

NCT01419574
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 2, 2026, 9:18 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of the EpiGlare Tester for the Measurement of Glare-Induced Changes in BSCVA in Subjects With and Without Cataracts

NCT04739397
View directory record Official record
Conditions
Cataract
Interventions
Glare Testing
Device
Lead sponsor
Epico, LLC
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 2, 2026, 9:18 PM EDT
Withdrawn Not applicable Interventional

Virtual Agent Feasibility in Oncology Patients (NTT Data)

NCT06682013
View directory record Official record
Conditions
Lung Cancer
Interventions
Virtual agent, Human agent
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Phase 2 Interventional Results available

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

NCT00780962
View directory record Official record
Conditions
Radiocontrast Nephropathy
Interventions
N-Acetylcysteine (NAC), 0.9% Sodium-chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 2, 2026, 9:18 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Birth to Three - Cavity Free

NCT05756413
View directory record Official record
Conditions
Caries,Dental
Interventions
Self-determination theory
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
16
States / cities
Anamosa, Iowa • Belle Plaine, Iowa • Cedar Rapids, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 9:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Spaeth/Richman Contrast Sensitivity Test

NCT01300949
View directory record Official record
Conditions
Glaucoma
Interventions
Spaeth/Richman Contrast Sensitivity Test, Pelli-Robson Contrast Sensitivity Chart
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 2, 2026, 9:18 PM EDT
Terminated Not applicable Interventional

4D Phase Contrast MR: Hypertrophy in Liver Cancer

NCT02618447
View directory record Official record
Conditions
Liver Cancer, Cancer of the Liver
Interventions
4Dimensional Phase Contrast Magnetic Resonance Angiography, Portal vein embolization
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 2, 2026, 9:18 PM EDT
Not listed Not applicable Interventional

Accuracy of the Thoracic Epidural Catheter Insertion Confirmed by Fluoroscopic Imaging

NCT01764932
View directory record Official record
Conditions
Patients Undergoing Thoracic Surgery, Patients Undergoing Upper Abdominal Surgery
Interventions
Fluoroscopic imaging
Procedure
Lead sponsor
Chicago Anesthesia Pain Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 2, 2026, 9:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

NCT04821284
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine Hydrochloride, Nab-paclitaxel, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Oxaliplatin, Perflubutane Microbubble, Contrast-Enhanced Ultrasound, Quality-of-Life Assessment, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Flemming Forsberg
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 2, 2026, 9:18 PM EDT